Evolocumab vs. Ezetimibe in Addition to Statins for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Hypercholesterolemia.

被引：0

作者：

Azuri, Joseph ^{[1
]}

Hammerman, Ariel ^{[2
]}

Arbel, Ronen ^{[3
]}

机构：

[1] Tel Aviv Univ, Family Med, Sackler Fac Med, Tel Aviv, Israel

[2] Clalit Hlth Serv, Med, Tel Aviv, Israel

[3] Sapir Coll, Med, Sderot, Israel

来源：

关键词：

Diabetes (Type II); Endpoint events; LDL; PCSK9; Efficacy;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A12027

引用

页数：2